2 weeks Ago By Defense World Staff
Spero Therapeutics ( NASDAQ:SPRO – Get Free Report ) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Spero Therapeutics to post earnings of ($0.27) per share for the quarter.
Spero Therapeutics Trading Down 0.8 % SPRO stock opened at $1.32 on Wednesday.
The stock has a market cap of $71.27 million, a PE ratio of 4.00 and a beta of 0.
63. Spero Therapeutics has a 12 month low of $1.01 and a 12 month high of $1.
89. The company has a 50-day moving average price of $1.30 and a 200 day moving average price of $1.
37. Wall Street Analyst Weigh In SPRO has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a report on Tuesday, August 6th.
HC Wainwright reduced their target price on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, November 4th.
Finally, TD Cowen raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. About Spero Therapeutics ( Get Free Report ) Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Featured Stories Five stocks we like better than Spero Therapeutics Earnings Per Share Calculator: How to Calculate EPS Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025 How to Invest in the Best Canadian Stocks Is Tesla’s Valuation a Bubble or Backed by Real Growth? The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Trucking Stocks Led the Pack Last Week: Can They Keep Rolling? Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
